GW-TT5

How it works

A gene therapy (Gateway Biotechnology) that uses an AAV virus to place designer receptors (DREADDs) on tinnitus-driving neurons, so they can be silenced on demand by an oral designer drug, a way to directly suppress the central hyperactivity many tinnitus mechanisms share. Preclinical: animal proof-of-concept shows brain delivery and effects on auditory perception, with a Phase 1 trial described as 'in preparation'.

This describes the treatment concept as reported in the cited research: a scientific mechanism, not a guarantee of clinical availability.